• Effective Risk Management When Using eCOA and ePRO

    Feb 25 | Clinical Research News Contributed Commentary | The use of direct source data capture in clinical research is on the rise, both during clinic visits and remotely by patients. This includes investigator-led and patient self-assessments using laptops or tablet devices, patient diary information using hand-held mobile devices, and wearable sensors that automatically record and transmit various health-related measurements (glucose levels, heart rate, etc.). More
  • Clinical Research As A Scientific Discipline: Birthing A Movement

    Feb 20 | Clinical Research News |ORLANDO—A day ahead of the 2020 Summit for Clinical Ops Executives (SCOPE), stakeholders from across the clinical trials enterprise convened for a campfire-style chat on ways to elevate the status of clinical research as a scientific discipline and foster collaboration and pre-competitive knowledge sharing to improve trial conduct. The SCOPE Scientific Symposium (SSS) was led by a half dozen leaders from AbbVie, Pfizer, Biogen, Boston Millennia Partners (BMP), and the Tufts Center for the Study of Drug Development (CSDD), with more than 50 others actively engaged in the dialogue. More
  • TrialScout Receives Top Honor At SCOPE’s Participant Engagement Awards

    Feb 19 | Clinical Research News | TrialScout receives the 2020 Participant Engagement Award for its #FindtheFive campaign, a social media campaign that uses TrialScout’s platform to harness the input from the over five million Americans that have participated in some form of clinical research over the past ten years. More
  • IBM Watson Health Launches Study Design and Authoring Tool

    Feb 18 | Clinical Research News| ORLANDO--IBM Watson Health today unveiled its newest cloud-based technology, IBM Study Advance, at the 11th Annual Summit for Clinical Ops Executives (SCOPE) in Orlando, Florida. The data-driven study design and authoring tool optimizes clinical trial protocol design by merging automated access to real-world patient population data, standardizing protocol template guidance and providing a collaborative workspace designed to facilitate efficiency. More
  • Phage Therapy Comes Of Age

    Feb 17 | Clinical Research News | Five years ago, phage therapy was a largely unknown approach to treating recalcitrant bacterial infections outside of Eastern Europe. But headline-grabbing stories of bacteriophages bringing people back from the brink of death has catalyzed interest in the century-old practice of using viruses to infect and kill disease-causing bacteria—especially now antimicrobial resistance has limited the usefulness of many antibiotics. More
  • Phages Provide Safety Net In Post-Antibiotic Era

    Feb 13 | Clinical Research News | To fully appreciate the potential of Adaptive Phage Therapeutics (APT), it’s helpful to review history through the lens of company co-founder and Chief Scientific Officer Carl Merril. For nearly five decades, Carl has been championing the idea of using bacteriophages to treat infectious diseases—an idea for which he has been variably applauded, questioned, ignored, scolded, and, ultimately, vindicated. More
  • Undoing Antibiotic Resistance With Phage Therapy

    Feb 12 | Clinical Research News | Perhaps no academic institution has worked longer on the clinical application of phages than Yale University where research efforts are focused on using the pathogen-fighting viruses to re-sensitize bacteria to the antibiotics they’ve grown resistant to. “We’re hoping to drive evolution in the other direction to preserve our antibiotic arsenal for longer,” says Benjamin Chan, Ph.D., associate research scientist in the department of ecology and evolutionary biology, who maintains a large natural-phage library. More
  • Phage Therapy: From Compassionate Use To Clinical Trials

    Feb 11 | Clinical Research News | At least three different types of phage products currently exist, and all of them are being explored as potential therapeutic remedies for people with drug-resistant bacterial infections. These include natural phages that have not been modified at all, as well as genetically engineered phages where one or more of their genes get modified to optimize their killing potential against a pathogen. More
View more articles
Learn with DIA! From drug safety and clinical statistics to regulatory affairs and benefit-risk assessment and management across the product lifecycle, DIA brings face-to-face training to you, all year long. Join for a day or two, or for a full week of expert-led education, with group discounts available.

Review and explore upcoming courses in 2020 at www.DIAglobal.org/RSIDM20.

Affiliated Reports Collection
Patient-centric pharma - Advancing the new business model  reveals how success can be achieved and provides food for thought on various ways to place patients firmly at the heart of your business and achieve commercially beneficial outcomes.